Recent Cleveland Clinic Cancer Center research shows the monoclonal antibody daratumumab is a safe, effective and fast-acting treatment for amyloid light-chain amyloidosis, producing a hematologic response in more than 80% of relapsed/refractory patients in a small cohort study.